Latest news with #ABBV
Forbes
3 days ago
- Business
- Forbes
6 Top-Yielding Dividend Stocks To Buy And Future-Proof Your Income
Passive income is the ultimate financial protection. And high-yielding dividend stocks are a great source for that low-maintenance cash flow. Choose the right companies, and you have a stream of rising cash payments you can reinvest or use to cover your bills. Choosing the right stocks is always the trick with investing. The best dividend stocks for you should align with your goals and risk tolerance, but the six introduced here may be worthy candidates. All pay yields of at least 3%—that's more than double the S&P 500 average—and have grown their revenue, free cash flow, dividend payments and market capitalization over the last five years. 6 Best High-Yielding Dividend Stocks For Future Income The table below highlights six top dividend stocks analysts love. A review of each company follows. Metrics are sourced from company reports and unless noted otherwise. For more investing ideas, see this list of the best stocks for 2025. 1. AbbVie (ABBV) AbbVie by the numbers: AbbVie is a global pharmaceutical company focusing on immunology, oncology, neuroscience, eye care and anti-aging treatments. AbbVie products are sold into 175 different countries. AbbVie has long been a popular choice among dividend investors. The pharma company pays $6.56 per share annually, and has implemented yearly dividend raises for more than 50 years. ABBV's stock price has also doubled over the past five years. AbbVie is successfully managing through the 2023 loss of patent protection on its hit product Humira. The strategy has included acquisitions and new immunology treatment launches. AbbVie merged with Botox-maker Allergan in 2020 to diversify its portfolio, and introduced Rinvoq and Skyrizi, which have now become top-selling treatments. AbbVie's revenue dipped 6.4% in 2023 but has since returned to growth. The company now expects adjusted diluted EPS of $12.12 to $12.32 in 2025, up from $10.12 in the prior year. 2. Phillips 66 (PSX) Phillips 66 by the numbers: Phillips 66 is an oil and gas company with five operating segments: midstream, chemicals, refining, marketing and specialties and renewable fuels. The company's assets include 70,000 miles of pipeline systems, 11 refineries and 1.8 million barrels per day (BPD) of crude capacity. The fuel brand portfolio includes Phillips 66, Conoco, 76 and JET. Phillips 66 pays shareholders $4.80 annually and has raised its dividend for 13 years. The company has also committed to keeping its dividend competitive and returning more than 50% of net operating cash flow to shareholders. The remaining operating cash flow is earmarked for debt reduction, share repurchases and growth initiatives. Phillips 66 is targeting total debt of $17 billion by 2027, down from the year-end 2024 balance of $20.1 billion. The focus on balance sheet health is appealing, as is Phillips 66's differentiated and integrated portfolio. Most of the EBITDA (38%) comes from refining, and the rest is split as double-digit percentages across marketing and specialties, midstream and chemicals. Over the last few years, Phillips 66 has made strategic divestitures and acquisitions to reduce costs, improve refinery utilization and improve overall value creation. 3. Chevron (CVX) Chevron by the numbers: Chevron is an integrated energy and chemicals company with two primary business segments: upstream and downstream. Upstream explores, develops, produces and transports crude oil and natural gas. Downstream refines and markets crude oil. Chevron is a solid choice for dividend investors who can handle energy sector volatility, thanks to its 4.5% yield, paying $6.84, and a 38-year history of raising shareholder payouts. The company is a major player in the global energy space and a top-five holding in Berkshire Hathaway's stock portfolio. Chevron relies on its integrated business model, financial strength and capital discipline to protect shareholder returns when oil prices decline. Chevron also recently acquired Hess Corporation, which is expected to provide significant cost synergies and improve long-term shareholder returns. Chevron CFO Eimear Bonner said the acquisition should "drive significant free cash flow and production growth into the 2030s." 4. Nexstar Media Group (NXST) Nexstar Media Group by the numbers: Nexstar is a diversified media company that produces and distributes news, sports and entertainment programming via owned and partner television stations and a suite of websites and mobile applications. The company generates revenue from advertising sales and retransmission fees. Cable and satellite TV providers pay broadcasters retransmission fees to provide broadcast content to subscribing customers. Nexstar pays an annual dividend of $7.44 per share and has raised its payout for 12 consecutive years. The company also spends a sizable portion of its adjusted free cash flow on share repurchases, which have reduced the share count by 34% since 2019. Nexstar has the largest local station network among major broadcast network owners like Televisa Univision, TEGNA and Fox. The company also owns two popular national networks, the CW and News Nation. These properties reach a combined 186 million households. The breadth of the portfolio is a competitive advantage—it's appealing to advertisers and provides operating cost efficiencies. Nexstar enjoys a high percentage of recurring revenue, high margins and strong cash flow. In 2024, recurring revenue was greater than 50%, the adjusted EBITDA margin was 37% and adjusted free cash flow topped $1.2 billion. The ad revenue is stable, but the digital portfolio and retransmission provide upside. Retransmission fees are negotiated at contract renewals, usually for three-year terms. In 2025, Nexstar will renew 60% of its subscriber base. 5. Fidelity National Financial (FNF) Fidelity National Financial by the numbers: Fidelity National Financial sells title insurance, closing and escrow services, annuities and life insurance. Fidelity pays an annual dividend of $2 per share and has raised its payout annually for 13 years. Title insurance is Fidelity's primary product, and the company enjoys top market share in the residential purchase, refinance and commercial markets. By state, Fidelity is the first or second market-share leader in 39 states. An industry-leading pretax title margin complements the strong competitive positioning and contributes to the company's strong free cash flow. Majority-owned subsidiary F&G Annuities & Life has also performed well for Fidelity, producing strong annuity sales and contributing $89 million or 28% to second quarter adjusted net earnings. 6. Clearway Energy (CWEN) (CWEN.A) Clearway Energy by the numbers: Clearway develops clean energy projects and produces clean energy through its portfolio of wind and solar assets. Clearway Energy has two share classes, A and C. The Class A shares (CWEN) have most of the voting power and higher trading volume. As a result, CWEN shares cost slightly more than CWEN.A shares. The distinction matters if you want to maximize your dividend yield. CWEN and CWEN.A have paid $1.71 per share over the past 12 months, but CWEN.A shares cost less and therefore have a higher yield. Clearway Energy is interesting because the company has strong revenue and cash flow growth and a commitment to raising its dividend—all packaged nicely within the renewable energy space. The company is securing future growth by optimizing its assets with repowerings, retrofits and capacity expansions. Clearway Energy also partners with sponsors on projects and pursues acquisitions independently. During its last earnings conference, Clearway raised its CAFD (cash available for distribution) guidance for the year and expressed confidence in meeting its 2027 CAFD per share targets. Bottom Line The best high-yield dividend stocks provide financial security. Opt for companies with a demonstrated commitment to increasing their dividends so you can enjoy those higher yields for years to come.
Yahoo
6 days ago
- Business
- Yahoo
AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?
North Chicago, Illinois-based AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. Valued at a market cap of $348.3 billion, it researches, develops, manufactures, and markets innovative medicines and therapies across a range of therapeutic areas. This healthcare giant has lagged behind the broader market over the past 52 weeks. Shares of AbbVie have gained 4.2% over this time frame, while the broader S&P 500 Index ($SPX) has surged 18.4%. Nonetheless, on a YTD basis, the stock is up 11%, outpacing SPX's 7.6% return. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Zooming in further, ABBV has outperformed the Invesco Pharmaceuticals ETF's (PJP) 2.1% drop over the past 52 weeks and 1.3% rise on a YTD basis. Shares of ABBV closed down marginally on Jul. 31, despite reporting stronger-than-expected Q2 earnings results. The company's revenue improved 6.6% year-over-year to $15.4 billion, surpassing consensus estimates by 2.3%. Further, its adjusted EPS came in at $2.97, up 12.1% from the prior-year quarter and 2.8% above analyst estimates. Additionally, ABBV raised its fiscal 2025 adjusted EPS guidance in the range of $11.88 to $12.08. While the stock edged lower that day, it rose 3.3% in the following trading session. For the current fiscal year, ending in December, analysts expect ABBV's EPS to grow 19.1% year over year to $12.05. The company's earnings surprise history is promising. It surpassed the consensus estimates in each of the last four quarters. Among the 27 analysts covering the stock, the consensus rating is a "Moderate Buy' which is based on 14 'Strong Buy,' two "Moderate Buy,' and 11 'Hold' ratings. This configuration is slightly less bullish than three months ago, with 15 analysts suggesting a 'Strong Buy' rating. On Aug. 4, Evan Seigerman from BMO Capital maintained a "Buy" rating on ABBV with a price target of $215, indicating a 9% potential upside from the current levels. The mean price target of $212.08 represents a 7.6% premium from ABBV's current price levels, while the Street-high price target of $255 suggests a notable upside potential of 29.3%. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-08-2025
- Business
- Yahoo
AbbVie Lifts Full-Year Guidance as Immunology Drugs Drive Quarterly Beat
AbbVie (ABBV) raised its full-year outlook on Thursday as the biopharmaceutical company recorded sec Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
01-08-2025
- Business
- Business Insider
M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics
U.S.-based AbbVie Inc. (ABBV) is reportedly in discussions to buy clinical-stage biotech company Gilgamesh Pharmaceuticals. According to sources familiar with the matter, the deal could be valued at around $1 billion for Gilgamesh. While talks are ongoing, an official announcement might come in the next few weeks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie develops innovative therapies for complex health conditions. Meanwhile, Gilgamesh is a clinical-stage biotech firm working on treatments for psychiatric conditions such as depression, anxiety, and PTSD. AbbVie Turns to M&A for Future Growth The potential deal would bolster AbbVie's pipeline of potential treatments for psychiatric disorders. Notably, Gilgamesh is developing neuroplastogens, a type of next-generation psychedelic compound. Notably, AbbVie continues expanding into mental health treatments after its blockbuster arthritis drug Humira lost U.S. patent protection in 2023, triggering a sales decline. The company now focuses on expanding its drug portfolio, supported by newer therapies and smart acquisitions. According to Reuters, the company has spent more than $20 billion on acquisitions since 2023 to offset its declining sales. Furthermore, the acquisition buzz comes more than a year after AbbVie and Gilgamesh entered into an option-to-license agreement to develop novel therapies for psychiatric disorders. As part of this partnership, AbbVie and Gilgamesh will jointly research and develop next-generation treatments for psychiatric disorders. Separately, the company will release its second-quarter results for 2025 on Thursday, July 31. Analysts on Wall Street expect AbbVie to post earnings of $2.88 per share in its upcoming quarterly report, up from $2.65 reported in the same period last year. Is AbbVie a Good Stock for 2025? On TipRanks, ABBV stock has a consensus Moderate Buy rating among 15 Wall Street analysts. That rating is based on nine Buys and six Holds assigned in the last three months. The average AbbVie stock price target of $209.33 implies an 11% upside from current levels.
Business Insider
31-07-2025
- Business
- Business Insider
Is ABBV Stock (ABBV) a Buy Ahead of Q2 Earnings?
Pharmaceutical giant AbbVie (ABBV) is set to release its Q2 earnings report this week. This has some investors wondering whether it's a good idea to buy shares of ABBV stock beforehand. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What Wall Street Expects Wall Street expects ABBV to report quarterly earnings of $2.95 per share in its upcoming report, which represents a year-over-year increase of 11.3%. Revenues are expected to come in at $15.04 billion, up 4% from the year-ago quarter. Will ABBV be able to beat these estimates? As can be seen below, it has a strong track record of doing just that in recent quarters. Key Insights Ahead of Earnings In the first quarter, ABBV reported an adjusted earnings per share of $2.46, surpassing the guidance midpoint by $0.10. Total net revenues for the quarter exceeded $13.3 billion, outperforming expectations by nearly $550 million. Notably, its ex-Humira platform exhibited a sales growth of over 21%, with strong performances across therapeutic areas such as immunology, neuroscience, oncology, and anesthetics. In Q2, AbbVie's revenue growth is likely to have been driven by higher sales of newer immunology drugs, Skyrizi and Rinvoq. Depression drug Vraylar and new migraine drugs — Ubrelvy and Qulipta – are also likely to have grown sales over the period. However, sales of its blockbuster immunology drug Humira are expected to keep falling after it lost patent protection in 2023. In its Oncology arm, analysts expect Imbruvica sales to have declined due to competition from new oral therapies. The company continues to invest, recently signing a licensing deal with New York-based Ichnos Glenmark Innovation for an investigational trispecific antibody targeting oncology and autoimmune diseases. It is also spending $10 billion in the U.S. to support expansion into new developing areas such as obesity. This is likely to have been part of the group's response to the threat of Trump tariffs on the pharmaceutical industry. Despite this, the ABBV share price has held up well this year, rising over 10%. Is ABBV a Good Stock to Buy Now? On TipRanks, ABBV has a Moderate Buy consensus based on 9 Buy and 6 Hold ratings. Its highest price target is $250. ABBV stock's consensus price target is $209.33, implying a 9.47% upside.
